Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease

IMPORTANCE: Despite hydroxyurea being an established treatment for sickle cell disease (SCD), it remains underused. The recent approval of the disease-modifying treatments (DMTs) l-glutamine, crizanlizumab, and voxelotor underscores the need to understand the uptake of DMTs in the current treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Newman, Terri Victoria, Yang, Jingye, Suh, Kangho, Jonassaint, Charles R., Kane-Gill, Sandra L., Novelli, Enrico M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665975/
https://www.ncbi.nlm.nih.gov/pubmed/37991760
http://dx.doi.org/10.1001/jamanetworkopen.2023.44546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665975/
https://www.ncbi.nlm.nih.gov/pubmed/37991760
http://dx.doi.org/10.1001/jamanetworkopen.2023.44546

Ejemplares similares